



## **Inologic Presents Promising Data at the Seventeenth Annual North American Cystic Fibrosis Conference**

### **Preclinical results show unique activity and safety profile of INO-4995**

SEATTLE, October 16, 2003 -- Inologic, Inc. today announced that it presented data on INO-4995, its lead compound for the treatment of cystic fibrosis. In preclinical testing to date, the compound has demonstrated a unique activity and safety profile. The results, from an abstract entitled "Preclinical Profile of an Inositol Polyphosphate Analog, INO-4995, a Candidate Therapeutic for Cystic Fibrosis", were presented by Beatrice Langton-Webster, Ph.D., vice president of drug development at Inologic, during the Seventeenth Annual North American Cystic Fibrosis Conference in Anaheim, CA.

In addition, an abstract prepared by Alexis Traynor-Kaplan, Ph.D., Inologic's Chief Scientific Officer, entitled "An Inositol Polyphosphate Analog, INO-4995, Inhibits Salt and Water Absorption Across CF Airway Epithelium" was presented as a poster at the meeting. Dr. Traynor Kaplan is also scheduled to present similar data at the Sixth Annual EMBL Symposium on Molecular Medicine, Defects of Secretion in Cystic Fibrosis on November 8<sup>th</sup>, 2003 in Heidelberg, Germany.

Dr. Langton-Webster's presentation detailed the promising mechanism of action of INO-4995. Mechanism of action studies indicate that INO-4995 is an ion channel modulator affecting both chloride and sodium ion channels. Additionally, INO-4995 specifically inhibits both fluid absorption and basal short circuit current in CF epithelial cells. These activities coupled with an excellent safety profile to date, make INO-4995 a promising candidate therapy for CF.

Inologic is developing an entirely new class of compounds for treating CF that regulate the sodium and chloride ions that control airway surface liquid volume. CF is characterized by a thick, sticky mucus that builds up in the lungs leading to chronic lung infections and inflammation over time. By regulating the sodium and chloride ions in the mucous membranes, it is hoped that INO-4995 will thin the mucous, leading to fewer lung infections and less inflammation.

"INO-4995 has the potential to improve the treatment of CF patients by rebalancing ion movement in lung tissue and consequently reducing the thick mucus buildup and the infections in the lungs of CF patients," said Dr. Langton-Webster. "We look forward to advancing INO-4995 into clinical development."

### **About Inologic**

Inologic, Inc. is the leading biopharmaceutical company in the discovery and development of a new class of therapeutics based on the study of inositol signaling molecules and their role in regulating key cell functions. Inologic believes its proprietary compounds can affect the signaling pathways that manage the cell functions linked to many serious diseases, including inflammation, cancer, diabetes, central nervous system disorders, cystic fibrosis, and diarrhea.

For more information on Inologic, please visit <http://www.inologic.com> or contact Ed Field, President and Chief Executive Officer at 206.448.9226.